Numbers included |
Number included in the quality improvement project (Appendix A available online at http://thorax.bmj.com/supplemental gives data on full cohort) | 503 |
Number of patients with full data for all four tools | 419 |
| |
Demographics |
Sex | 47% male (n = 197) |
Age | Median (range) = 74 (16–98) years |
| Age >65 years = 70% (n = 292) |
Living in own home | 84% (n = 351) |
Living alone | 36% (n = 152) |
| |
Clinical characteristics |
Antibiotic from GP before admission | 42% (n = 149/356) |
CRP >50 | 76.5% (n = 286/374) |
Chest radiograph consistentwith pneumonia | 95% (218/230) |
| |
Severity assessment on admission |
CURB65 score | |
0 or 1 | 33.5% (n = 140) |
2 | 28.5% (n = 119) |
⩾3 | 38% (n = 160) |
Respiratory rate ⩾30/min | 22% (n = 91) |
Systolic blood pressure <90 mm Hg | 6% (n = 24) |
Diastolic blood pressure ⩽60 mm Hg | 25% (n = 103) |
Pulse ⩾125/min | 10% (n = 43) |
Pulse oximetry <92% (any FiO2) | 33% (n = 140) |
Blood urea >7 mmol/l | 58% (n = 242) |
New confusion | 31% (n = 129) |
% without comorbidity | 35% (n = 147) |
% with asthma/COPD | 35% (n = 146) |
Initial antibiotic regimen |
Broad spectrum betalactam + macrolide | 48% (n = 201) |
Narrow spectrum betalactam + macrolide | 31% (n = 130) |
Betalactam monotherapy | 10% (n = 42) |
Macrolide monotherapy | 3% (n = 13) |
Levofloxacin | 2% (n = 8) |
Others | 6% (n = 25) |
Outcomes |
% of patients transferred to theintensive care unit | 3% (n = 13) |
30-day post admission mortality | 19% (n = 79) |
Length of hospital stay (excludes deaths) | Median (range) = 5 (0–116) days |